Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Return on Capital Employed (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Return on Capital Employed over the past 12 years, most recently at 0.54% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.54% for Q4 2025, down 12.0% from a year ago — trailing twelve months through Dec 2025 was 0.54% (down 12.0% YoY), and the annual figure for FY2025 was 0.48%, up 4.0%.
  • Return on Capital Employed for Q4 2025 was 0.54% at Viridian Therapeutics, Inc.\DE, up from 0.62% in the prior quarter.
  • Over the last five years, Return on Capital Employed for VRDN hit a ceiling of 0.33% in Q4 2022 and a floor of 1.28% in Q2 2021.
  • Median Return on Capital Employed over the past 5 years was 0.52% (2025), compared with a mean of 0.61%.
  • Biggest five-year swings in Return on Capital Employed: soared 115bps in 2021 and later tumbled -33bps in 2023.
  • Viridian Therapeutics, Inc.\DE's Return on Capital Employed stood at 0.4% in 2021, then grew by 17bps to 0.33% in 2022, then tumbled by -100bps to 0.66% in 2023, then soared by 37bps to 0.42% in 2024, then dropped by -29bps to 0.54% in 2025.
  • The last three reported values for Return on Capital Employed were 0.54% (Q4 2025), 0.62% (Q3 2025), and 0.65% (Q2 2025) per Business Quant data.